Las Vegas casino mogul Steve Wynn suggested Sunday that Stephen Paddock would have set off alarm bells at his properties had he tried launching his mass murder from one of them. Wynn, namesake of the glitzy Wynn Las Vegas on the strip, said his housekeeping staff is trained to do a visual inspection any time...
NYS Entity Status
NYS Filing Date
FEBRUARY 12, 2014
NYS DOS ID#
SPIEGEL & UTRERA P.A. P.C.
1 MAIDEN LANE, 5TH FLOOR
NEW YORK, NEW YORK, 10038
NYS Entity Type
DOMESTIC PROFESSIONAL CORPORATION
2014 - LETS WYNN OCCUPATIONAL THERAPY P.C.
Around the Web
- Vegas shooting wouldn’t have happened at my casino: Steve Wynn
By Marisa Schultz - Sunday Oct 8, 2017
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- Hiring a shrink could make your company more successful
By Moneyish - Monday Sep 4, 2017
This isn’t the kind of occupational therapy you’re used to. When Jonathan Pellegrin, the former chairman and CEO of publishing company Johnson Hill Press and author of “The Art of Selling the Family Business,” saw trouble brewing at his company, he knew just where to turn: a therapist specializing in workplace issues. With a history...
- Is Luis Severino suddenly the most prized pitcher in NY?
By Ken Davidoff - Sunday Aug 6, 2017
CLEVELAND — Do we have a new King of the Hill in New York? You’re starting a third team in the Tri-State area — let’s call them the Paramus Mall Rats — and you get to choose one pitcher from either the Yankees or the Mets. Whom do you choose? You have to give ultra-serious...
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]